Study:
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
Rationale:
n/a
Purpose:
This will be a randomized blinded clinical trial. Patients will be randomized to receive
either a remifentanil or dexmedetomidine infusion for general anesthesia. The anesthesia
team will know the result of randomization at induction. Data will be gathered by research
personnel who will be blinded to the anesthetic method used. Patients will be blinded to
the anesthetic they receive till they are discharged from the PACU when they will have the
option to be unblinded. The Data Safety and -Toxicity Committee will review all serious
adverse events and toxicity reports as well as annual reviews.
Study Status: Recruiting
Recruiting:
Gretchen Upton, B. Psych 216-444-3289 uptong@ccf.org
Gretchen Upton 216-444-3289 uptong@ccf.org
| Condition |
Intervention |
Phase |
Adult Intracranial Tumor
Adult Solid Tumor |
Drug: Remifentanil
Drug: Dexmedetomidine |
Phase 2/Phase 3 |
Verified by
Outcomes Research Consortium
February, 2013
Sponsored by: Outcomes Research Consortium
Information provided by: Outcomes Research Consortium
ClinicalTrials.gov identifier: NCT01269918
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
Shobana Rajan, MD., Principal Investigator